Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Total Revenue of $958.40 million for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $958.40M +432.1% |
$180.13M | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue (ASC 606) | $958.40M +432.1% |
$180.13M | $0.00 | $0.00 | — | — |
| Net Income | -$288.28M +38.1% |
-$465.89M -24.7% |
-$373.63M -26.5% |
-$295.35M -22.1% |
-$241.85M -19.6% |
-$202.24M -140.9% |
| Diluted EPS | -$12.85 +41.3% |
-$21.90 -9.6% |
-$19.99 -16.0% |
-$17.23 -17.8% |
-$14.63 -11.8% |
-$13.09 |
| Total Assets | $1.26B +20.9% |
$1.04B +62.7% |
$640.55M +76.7% |
$362.57M +32.6% |
$273.33M -4.8% |
$287.00M -35.1% |
| Cash and Equivalents | $198.69M +98.7% |
$100.02M +0.1% |
$99.92M -69.9% |
$331.55M +814.1% |
$36.27M -32.8% |
$54.00M +15.6% |
| Long-Term Debt | $339.88M +189.1% |
$117.57M +1.8% |
$115.48M +134.3% |
$49.29M | $0.00 | — |
| Stockholders Equity | $602.69M -20.1% |
$754.38M +86.1% |
$405.33M +105.3% |
$197.39M +0.7% |
$196.11M -18.3% |
$239.97M -42.4% |
| Operating Income | -$300.10M +39.7% |
-$497.88M -30.8% |
-$380.50M -29.6% |
-$293.57M -21.1% |
-$242.48M -17.3% |
-$206.67M -117.6% |
| Shares Outstanding | 22.84M +3.8% |
22.00M +10.7% |
19.88M +9.8% |
18.10M +5.8% |
17.10M +10.3% |
15.51M +0.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $287.27M | +362.0% | +35.0% |
| Revenue (ASC 606) | September 30, 2025 | $287.27M | +362.0% | +35.0% |
| Net Income | September 30, 2025 | -$114.19M | -6.8% | -170.1% |
| Diluted EPS | September 30, 2025 | -$5.08 | -3.3% | -167.4% |
| Total Assets | September 30, 2025 | $1.36B | +26.9% | +34.2% |
| Cash and Equivalents | September 30, 2025 | $295.69M | +27.1% | +58.8% |
| Long-Term Debt | September 30, 2025 | $339.75M | +190.2% | +187.0% |
| Stockholders Equity | September 30, 2025 | $625.73M | -19.5% | -10.1% |
| Operating Income | September 30, 2025 | -$113.97M | +2.0% | -141.5% |
| Shares Outstanding | September 30, 2025 | 22.70M | +4.1% | +2.2% |
- MADRIGAL PHARMACEUTICALS, INC. reported Total Revenue of $958.40 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +432.1% in Total Revenue compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $958.40 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +432.1% in Revenue (ASC 606) compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Net Income of -$288.28 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +38.1% in Net Income compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Diluted EPS of $12.85 per share (loss) for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +41.3% in Diluted EPS compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Total Assets of $1.26 billion for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +20.9% in Total Assets compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Cash and Equivalents of $198.69 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +98.7% in Cash and Equivalents compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Long-Term Debt of $339.88 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +189.1% in Long-Term Debt compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Stockholders Equity of $602.69 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed a decrease of -20.1% in Stockholders Equity compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Operating Income of -$300.10 million for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +39.7% in Operating Income compared to the prior fiscal year.
- MADRIGAL PHARMACEUTICALS, INC. reported Shares Outstanding of 22.84 million shares for fiscal year 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +3.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: